Ruxolitinib Cream Hit 79% Response Rate in HS Phase 2 Trial
A phase 2 trial found ruxolitinib 1.5% cream (Opzelura) produced a 79% response rate in mild to moderate hidradenitis suppurativa. Phase 3 trials are now underway.
Topic: Clinical Trials
Bempikibart Cut Hair Loss Scores 35.3% in Alopecia Areata Trial
Q32 Bio's bempikibart cut SALT hair-loss scores by 35.3 percent at week 36, with 40 percent of severe alopecia areata patients reaching SALT-20 — even after failing JAK inhibitors.
